anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman \& Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
The invention relates to a radiation-resistant preparation, and the preparation method and the application thereof. The preparation comprises the following raw materials in parts by weight: 70 to 80 parts of cordate houttuynia, 15 to 25 parts of honey and 5 to 15 parts of American ginseng. The radiation-resistant preparation prepared in the invention is free from additives such as coloring matters, spices, preservatives, water and the like, and is completely made of natural materials. The radiation-resistant preparation is soft in taste, is a basic product and mild wine with the alcohol content of 6 to 10 degrees, can be taken by people even with low drinking capability, and also can be taken by children after being added with water for dilution. Through reasonable compatibility of the cordate houttuynia, the honey and the American ginseng, as well as an applicable preparation method including a fermentation process, the radiation-resistant preparation is enabled to achieve preventing and radiation resisting effects. In addition, the radiation-resistant preparation also can play effects on other diseases. The radiation-resistant preparation provided by the invention has the advantages that types of the raw materials are fewer, an obvious effect can be achieved, limitations from production spots are avoided, and the applicable human populations are wide.
FIELD: medicine; pharmaceutical engineering. SUBSTANCE: composition has powder of Californian poppy (Escholzia californica Cham), powder of linden (Tilia cordata Mill. ), powder of big daisy flowers (Tanaceum parthenium), thiamine nitrate, pyridoxine hydrochloride, cyanocobalamine, dehydrated silicon dioxide, maltodextrine, magnesium stearate. Medicament powders are produced by applying cryogenic comminution at -50 -80 C temperature and have mean particle size equal to 300-400 mcm. EFFECT: high degree of bioavailability; enhanced effectiveness of treatment. 2 cl
The present invention relates to an application of teprenone (geranylgeranylacetone, GGA) for resisting heatstroke. Under the condition of peroral administration, the teprenone can obviously delay rat heatstroke in a heat environment and prolong surviving time of the rate with heatstroke. Different concentration of teprenone is given to adult rats by gavage, subsequently the rat heatstroke and the surviving time of the rate are observed. The result shows that a certain concentration of teprenone given by gavage in advance can obviously delay the rat heatstroke in the heat environment, and prolong the surviving time of the rat with heatstroke, and improve the anti-heatstroke ability. Through the method of the invention, the common medicine teprenone with a proper dosage is taken at a proper time, which can improve the rat anti-heatstroke ability, and provide powerful evidence for human experiment. If the method can be popularized to human application, better economic benefit and social benefit can be achieved.
OBJECTIVE: Expanding on previous investigations, this study aims to elucidate the role of lipid metabolism disorders in the development of intracranial atherosclerotic stenosis (ICAS) and the determination of stroke risk. The primary objective is to explore the connections between lipid parameters and acute ischemic stroke (AIS), while also examining the potential mediating influence of fasting glucose levels.
METHODS: Retrospectively, we collected data from symptomatic ICAS patients at the First Affiliated Hospital of Soochow University, including their baseline information such as medical histories and admission blood biochemical parameters. Stenotic conditions were evaluated using magnetic resonance imaging, computed tomography angiography, or digital subtraction angiography. The associations between lipid parameters and AIS risks were investigated via multivariate logistic regression analysis.
RESULTS: A total of 1103 patients with symptomatic ICAS were recruited, among whom 441 (40.0%) suffered new ischemic events during hospitalization. After adjusting for confounding factors, the RCS curves exhibited a dose-response relationship between the atherogenic index of plasma (AIP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and AIS. Further multivariate analysis revealed significant associations between these parameters and AIS. Furthermore, mediation analysis indicated that fasting blood glucose (FBG) acted as a mediator in the association between lipid parameters (AIP, TC, and TG) and AIS.
CONCLUSION: Higher lipid parameters in ICAS patients, particularly AIP, TC, and TG, were associated with an increased AIS risk. Additionally, FBG may mediate stroke risk in ICAS patients, highlighting the need for further exploration of underlying mechanisms.
The aim of this study is to assess the effects of a facilitation-based improvement intervention on three primary performance outcomes: (1) staff reported use of best practices, (2) measures of staff work engagement and job satisfaction, and (3) resident quality of care. Within the context of the Translating Research in Elder Care study (Pro00037937), the influence of staff characteristics related to work performance and unit context scores (leadership, culture, resources) on the three primary outcomes will be assessed Background Translating Research in Elder Care (TREC) is an ongoing applied research program that began in 2007. TREC is focused on practical solutions that will improve quality of care provided to nursing home residents, enrich the work life of their caregivers, and enhance system efficiencies and effectiveness. In TREC 1, teams of researchers worked together with decision makers from the residential long term care (LTC) sector on multiple studies in Manitoba, Saskatchewan, Alberta and to a lesser extent, British Columbia (SCOPE pilot only). Data were collected from approximately 4000 care providers and residents using the Resident Assessment Index Minimum data Set (RAI-MDS) 2.0 in participating TREC nursing homes.

TREC has already established its value to the health system by demonstrating improvements in resident care, clinical outcomes, and staff well-being. Information data collected from over 100,500 resident assessments combined with the staff and facility surveys now forms the TREC Measurement System (TMS Project). This wealth of data has informed the SCOPE pilot project in 2010 and SCOPE was conceived as a result of this data.

The SCOPE intervention is designed as a randomized controlled trial (RCT). For our primary outcome measure (change in Conceptual Research Use (CRU)between pre and post intervention periods) a sample size of 34 units per arm is adequate to detect an effect size of 0.67 or greater (using the standard deviation for the change in CRU between pre and post intervention periods for intervention and non-intervention from the SCOPE pilot data at 80% power, with an alpha 0.05, for a 2-tailed comparison of independent samples. The intervention will take place in as many as 45 of the facilities involved in the TMS project (Pro00037937) to take account of drop -outs. Each facility will have a Senior Sponsor (generally the Director of Care or Exec Director). Participants in the intervention teams will be from a single unit in each intervention facility and will include 3 Health Care Aides who will lead the team, as well as 2 other members of that unit which can include other allied professional staff, nurses, and Occupational Therapist /Rec Aides. One member of the team must be the Team sponsor (generally the unit's care manager) removes obstacles for the team.
The invention provides a traditional Chinese medicine formula for nourishing kidney, promoting blood circulation and dredging collaterals, and belongs to the field of traditional Chinese medicine. The formula of the traditional Chinese medicine consists of the following raw materials: Curculigo orchioides Gaertn., Cnidium monnieri, Morinda officinalis, Herba Epimedii, Cistanche, solomon's seal, raspberry, the fruit of Chinese magnoliavine, medlar, ophiopogon root, American ginseng, red ginseng, Acanthopanax senticosus, pseudo ginseng, astragalus root, white atractylodes rhizome, Poria cocos, licorice, Rehmannia glutinosa, Chinese angelica, Ligusticum wallichii, Radix Paeoniae Alba, and pure grain liquor. The invention further provides a preparation method of the traditional Chinese medicine formula for nourishing kidney, promoting blood circulation and dredging collaterals. The raw materials of the invention are natural drugs and have no drug resistance, no residue and no side effects. In addition, the formula of the invention is ingenious, and properly matches the rigid and flexible materials to mutually promote and assist, multiply the effect, and reach the effect of enrichment without dryness. Moreover, the traditional Chinese medicine reaches balance of yin and yang of the body, enriches qi and blood, and can actively and effectively improve sexual desire and sexual ability of the elderly. Finally, the traditional Chinese medicine is soaked in liquor into a medicinal liquor, which is convenient for administration, easy to store, and simple for production.
PURPOSE:To provide a drug preparation for skin application containing powder of shell membrane, having wound-remedying action and dermatic cell proliferating action and useful for the remedy of various wounds. CONSTITUTION:The objective drug contains powder of shell membrane as an active component. The powder of shell membrane is produced by collecting shell membrane from egg of chicken, duck, goose, quail, etc., and physically and/or mechanically pulverizing the shell membrane. The use of shell membrane of chicken which is easily available in large quantity is especially preferable. The powder is produced preferably by removing egg liquid from egg shell, breaking the shell to a proper size, separating and collecting the shell membrane from the shell under stirring and drying the collected membrane preferably to a water-content of <=5%. The pulverization is preferably carried out at a low temperature as far as possible to prevent the denaturation of the membrane at high temperature. The size of the powder is preferably about 0.01-1,000mum, especially about 0.1-200mum.
The invention discloses an application of gamabufotalin in preparing a medicine for treating liver cancer, and belongs to the technical field of cancer medicines. The embodiment of the invention proves the application of the gamabufotalin in preparing the medicines for treating liver cancer. The dosage of the gamabufotalin is 20mg/kg. The embodiment of the invention demonstrates that the gamabufotalin CS-6 has obvious growth inhibition effect on liver cancer cells, obvious invasion inhibition capability on liver cancer cells and obvious proliferation inhibition potential on liver cancer cells; simultaneously, the gamabufotalin CS-6 has therapeutic effect on the animal model of liver cancer. The gamabufotalin CS-6 can obviously reduce the volume and weight of liver cancer tumor after being administered at 20mg/kg, has obvious effect of inhibiting liver cancer tumor, can be applied to preparation of medicaments for treating liver cancer, and provides choices for expanding novel medicaments for treating liver cancer. The component of the gamabufotalin is single, and no obvious toxic or side effect exists; compared with the existing toad preparation, the preparation has more remarkable clinical medicinal value.
Psoriasis is a debilitating, chronic inflammatory skin disorder characterized by scaly skin patches caused by infiltration of inflammatory cells into the dermis and epidermis, with secondary epidermal cell (keratinocyte) hyperproliferation. Psoriasis is a complex disease and a combination of genetic and environmental factors are likely to be causative. T-cell-mediated immune process, including cytokines (eg. IFN-γ) and chemokines, play an essential role in psoriasis. Susceptibility genes for psoriasis map to PSORS1 in the HLA region at chromosome 6p21, PSORS2 in the chromosome 17q24-q25, and others.

Recently our colleagues in the Academia Sinica and we performed a genome-wide linkage analysis with polymorphic microsatellites in one five-generation affected psoriasis kindred, and the result revealed a close linkage at D17S928, close to CD7. CD7+ T cells produce IFN-γ when activated, and have been located in skin inflammatory lesions. Therefore, in this study we first want to examine the role of CD7 in skin inflammations conditions. CD7+ cells will be stimulated by a variety of methods, and will be used to treat keratinocyte cultures or be injected intradermally to mice. We will watch for skin inflammation and possible proliferation and changes in keratinocytes. Possible changes in CD7 function in patients with psoriasis will be explored, for example, polymorphisms of the CD7 gene may predispose skin inflammation and abnormal interaction with the keratinocytes. CD7- T cells, which could be derived from CD7+ cells and are enriched in skin inflammation lesions, secrete the Th2 cytokine IL-5. We are also interested in the mechanism and the consequences of this CD7 shift. We hope this study will be helpful in the understanding and management of skin inflammation conditions, including psoriasis.
Belonging to the fields of phytochemistry, Chinese herbal preparation and diabetes prevention and treatment, the invention relates to a composition that is extracted from medicinal and edible plants and able to adjust postprandial and fasting blood glucose simultaneously. The composition is characterized by employing medicinal and edible substances of mulberry leaves and cinnamomum cassia and is composed of extracts of the two sunstances, wherein, the mulberry leaf extract accounts for 1-99% by weight and the relevant cinnamomum cassia extract accounts for 99-1% by weight. The preparation method of the mulberry leaf extract and the cinnamomum cassia extract comprises the steps of extraction, adsorption, elution and drying, etc. The two extracts are taken according to the formula ratio and are subjected to sterile mixing for 10-60min, so that the composition needed can be obtained. Results of in vitro and in vivo pharmacodynamic tests on animals indicate that the composition of the invention can reduce postprandial blood glucose and fasting blood glucose. The composition of the invention can be adopted as a raw material for preparing food, health care products and Chinese herbal preparations according to requirements so as to be applied in postprandial and fasting blood glucose adjustment, diabetic complication prevention and obese people weight reducing. The composition provided in the invention entirely employs edible substances as the raw materials and is free of chemical glucose-lowering medicaments as well as chemical substances like chromium picolinate, therefore, the composition is characterized by high security.
Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
This is a single-center, open-label (all people know the identity of the intervention), sequential design study in healthy men. All participants will receive ibrutinib on Day 1 and ibrutinib in combination with ketoconazole on Day 7. Food will be restricted from the evening before dosing until 4 hours after dosing on Days 1 and 7. Following an overnight fast, ketoconazole will be given on Days 4 to 6, 1 hour prior to ibrutinib dosing on Day 7, and again on Days 8 and 9. All ibrutinib and ketoconazole doses will be administered with water. The participants will leave the study center on Day 10.
The present invention relates to the delivery of physiologically active compounds through an inhalation route. Specifically, it relates to aerosols containing physiologically active compounds that are used in inhalation therapy. In a composition aspect of the present invention, the aersosol comprises particles comprising at least 5 percent by weight of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. In a method aspect of the present invention, chloridazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, on hyoscyamine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of chlordiazepoxide, betahistine, clondine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine; and, b) a device that forms a chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine containing aerosol from the composition, for inhalation by the mammal.
Cardiovascular disease (CVD) is the leading cause of death in the United States, accounting for \~830,000 deaths annually. Oxidative stress and inflammatory responses are fundamental mechanisms leading to vascular endothelial dysfunction because of their role in reducing nitric oxide (NO) bioavailability. Greater intakes of dairy foods have been associated with a lower incidence of CVD-related morbidity. Although the mechanisms by which dairy protects against CVD remain unclear, epidemiological and experimental evidence suggest that the concerted actions of bioactive milk-derived peptides and micronutrients may protect against hypertension and future CVD risk by improving vascular endothelial function. Therefore, the objective of this study is to define the mechanisms by which the acute consumption of low-fat milk protects against postprandial vascular endothelial dysfunction by reducing oxidative stress responses that limit NO bioavailability to the vascular endothelium. In this study, participants having the metabolic syndrome will ingest low-fat milk or rice milk on a single occasion. Then, vascular function and biomarkers of oxidative stress and NO metabolism will be monitored at 30 min intervals throughout a 180 min postprandial period. Collectively, these studies will help identify how postprandial vascular function is regulated in individuals at high-risk for CVD, and whether low-fat dairy consumption can be used as a strategy to better improve vascular function.
A group of novel expanded porphyrin-like compounds, porphacyanine (Pc) and porphacyanine-like compounds, having absorption maxima in the range of 400-850 nanometers is useful in detecting and treating targeted tissues, cells and viruses. The use of the Pc of the invention permits the irradiation to comprise wavelengths other than those absorbed by blood. The Pc of the invention may also be conjugated to target-specific moieties such as immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits greater depth of treatment penetration and greater specificity in targeting tissues or cells. Coupled with an appropriate paramagnetic ion or radioisotope, the Pc of the invention is suitable for use in nuclear magnetic resonance imaging and radioimaging. Novel methods for synthesizing the Pc of the invention are disclosed.
Vascular endothelial growth factor receptor 2(VEGFR2) is essential target for tumor angiogenesis, and VEGFR2-169 induces specific Cytotoxic T lymphocytes (CTL) against VEGFR2 expressed targets. VEGFR2-169 shows strong anti-tumor effects restricted to HLA-A\*2402 in vitro, and this peptide induces CTL from cancer patients. 60% in Japanese population have HLA-A\*2402. VEGFR2-169 is suitable for clinical trial, and gemcitabine has been approved against pancreatic cancer. Gemcitabine is reported to improve immune-response, therefore synergistic effect between vaccine therapy and chemotherapy will be expected. In this clinical trial, we evaluate the safety, tolerability and immune response of different doses of VEGFR2-169 emulsified with Montanide ISA 51 in combination with gemcitabine and to determine the recommended phase II dose of peptide.
This is a multicenter, observational study of participants receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 360 participants across \~50 care centers in Europe and other regions over a period of \~ 2 years. The study population will include participants who are receiving usual care treatment with commercial supply of Translarna (or receiving care within a named participant early access program) and who provide consent. Participants will be followed for at least 5 years from their date of enrollment. Safety and efficacy data will be collected in conjunction with routine visits conducted as per usual care. Although there are no protocol-mandated procedures, it is expected that physicians and other caregivers will follow published treatment guidelines and standards of care.
BACKGROUND: Cytomegalovirus retinitis (CMVR) is a well-described complication of CMV disease in immunocompromised hosts. While robust data exists for CMVR in patients with acquired immunodeficiency syndrome (AIDS), the incidence and risk factors for CMVR in solid organ transplant recipients (SOTR) with CMV viremia are less defined.
METHODS: We performed a retrospective cohort study of SOTR who had CMV viremia and underwent routine ophthalmologic examination between 1/1/2018 and 3/16/2022. Univariate statistics were performed to evaluate risk factors for development of CMVR.
RESULTS: Overall, 38 patients were included, primarily kidney (78.9%), heart (7.9%), and liver (7.9%) transplant recipients. Five patients (13.2%) developed CMVR during the study period. CMVR was diagnosed an average 281 days after index transplantation, 84 days from the most recent rejection episode, and 69 days from onset of viremia. Only 1 patient (20%) had symptoms at the time of CMVR diagnosis. CMVR was associated with preceding allograft rejection as well as transplanted organ type.
CONCLUSION: While CMV tissue disease more commonly manifests in other organs, CMVR occurred relatively frequently in this group of high-risk SOTR with CMV viremia. As most of the patients in our study did not have ocular symptoms at the time of diagnosis, routine ophthalmologic screening should be considered in SOTR with CMV viremia.